$Bob's and Jbem's Bitchin' Bios

[buckiii2]

Awesome news on the 1st abstract
None of the 4 patients in low dose has died and the one in the mid steroid group is alive at 11 months.

The 4 low dose are alive at 9.5, 10, 11 and 23.5 months. That is proof that IL-12 is working.

Very important news. The 12.5 months survival ignores the 4 patients alive at less than 12.5 months. The 4 are at 9.5 to 11 months. So the survival will be more than 12.5 months my Jan 2018 and it is impossible to know how much higher it will go.

The low dose could be over 12.5 months before one of the 4 die. Amazing to imagine what the survival data will look like when the trial ends.

This all bores well for phase 3.

http://www.ziopharm.com/content/02-pipeline/03-presentations-publications/1-22nd-annual-meeting-and
-education-day-of-the-society-for-neuro-oncology-sno-in-san-francisco/2-phase-1-study-of-ad-rts-hil-
12-veledimex-in-adult-recurrent-glioblastoma/2017sno_chiocca_ph1studyad-rts-hil-12veladultrgbm.pdf